Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /News

News

New research shows drug used for arthritis can treat blood cancer - Pharmaceutical Technology

A new study funded by the UK Medical Research Council (MRC) has revealed that the arthritis drug methotrexate (MTX) can be used to treat patients with a type of blood cancer, polycythemia vera (PV).

PV results in an overproduction of red blood cells that causes itching, headaches, weight loss, fatigue and night sweats.

The...Read More »


Brazilian Society of Rheumatology working with Ministry of Health to i

The US Food and Drug Administration (FDA) has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy.

This product, expected to become commercially available in both 40mcg and 80mcg strengths to patients by prescription during the first quarter of...Read More »


FDA nod for breath-actuated QVAR inhaler

The US Food and Drug Administration (FDA) has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy.

This product, expected to become commercially available in both 40mcg and 80mcg strengths to patients by prescription during the first quarter of...Read More »


New inhibitor drug shows promise in relapsed leukemia: Researchers used gilteritinib to target a common mutation -- ScienceDaily

A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center. The Fms-like tyrosine kinase 3 (FLT3)...Read More »


Experimental cancer drug shows promise: New study suggests GGTI-2418 can block one specific protein from binding to and degrading another protein known for killing cancer cells. -- ScienceDaily

A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center’s Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology at New York University’s Langone Medical Center, led to the publication of an important study in the latest issue of Nature....Read More »


How to reprogram cells in our immune system: The discovery could improve treatments for autoimmune diseases and cancer -- ScienceDaily

When the immune system is imbalanced, either due to overly-active cells or cells that suppress its function, it causes a wide range of diseases, from psoriasis to cancer. By manipulating the function of certain immune cells, called T cells, researchers could help restore the system’s balance and create...Read More »


JMC wins Presidential Export Award from Department of Commerce

Today, U.S. Secretary of Commerce Wilbur Ross honored 32 U.S. companies and organizations that export goods and services during the 2017 President’s “E” Awards ceremony.

JMC Inc., a Durham N.C. based company, won the President’s E-Award for Excellence in Export 2017, and it is the only...Read More »


Bacteriophages, natural drugs to combat superbugs -- ScienceDaily

Viruses that specifically kill bacteria, called bacteriophages, might one day help solve the growing problem of bacterial infections that are resistant to antibiotic treatment. Researchers at Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center have determined that phages can effectively reduce bacterial levels...Read More »


Fungi have enormous potential for new antibiotics -- ScienceDaily

Fungi are a potential goldmine for the production of pharmaceuticals. This is shown by researchers at Chalmers University of Technology, who have developed a method for finding new antibiotics from nature’s own resources. The findings — which could prove very useful in the battle against antibiotic resistance —...Read More »


FDA grants Breakthrough Therapy designation to Novartis CTL019 for DLBCL - Pharmaceutical Technology

Novartis’ investigational chimeric antigen receptor T-cell (CAR-T) therapy, CTL019, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) to treat adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

The CTL019 will be administered to those patients who have failed two or more...Read More »


Older Entries »